Treatment of Peri-implant Mucositis and Supportive Peri-implant Therapy

Inclusion criteria: 1. Age 18 to 85 years. 2. Healthy systemic conditions (American Society of Anesthesiologists classification (ASA) I or II: systemically healthy or suffer from mild to moderate, but well controlled systemic diseases). 3. Must have at least one osseointegrated dental implant with the following conditions (Berglundh et al. 2018a). * At least 12 months since the prosthesis was placed. * Absence of bone loss beyond crestal bone level changes from initial bone remodeling. * For implant mucositis subjects: Presence of bleeding and/or suppuration on gentle probing around implant at least 2 sites. Visual inspection demonstrating the presence of peri-implant signs of inflammation. * For healthy implant subjects: Absence of bleeding and/or suppuration on gentle probing around implant. 4. Have a current (less than 6 months old) x-ray of the affected site 5. All participants must be enrolled in a 3 to 6 months maintenance recall program including teeth/implants prophylaxis and supportive periodontal therapy. Exclusion criteria: 1. Poorly controlled diabetes mellitus (HbA1c \>6.5). 2. Uncontrolled systemic disease or condition known to alter bone metabolism. (e.g. osteoporosis, osteopenia, hyperparathyroidism, Paget's disease) 3. Current smokers or vapers. 4. Pregnancy or could be pregnant (self-reported), or plan to be pregnant in the next 6 months. 5. Long-term (3 months) intake of anti-inflammatory medications (e.g. non-steroidal anti-inflammatory drugs (NSAIDs)) known to affect periodontal status within one month previous to participation in the study. 6. Taking corticosteroids. 7. Long-term antibiotic use (\> one weeks) within three months previous to participation in the study. 8. No history of supragingival scaling or non-surgical therapy at the affected implant site in the last 1 month. 9. Taking anticoagulant medications. 10. Subjects who require prophylactic antibiotics.